Gorilla Technology Shares Repurchase and Insider Ownership Updates; To Announce Q1 Earnings
London, United Kingdom--(Newsfile Corp. - May 22, 2025) - Gorilla Technology Group Inc. (NASDAQ: GRRR) ('Gorilla' or the 'Company'), a global solution provider in Security Intelligence, Network Intelligence, Business Intelligence and IoT technology, today announced a series of significant developments underscoring its confidence in long-term value creation and sustained operational momentum.
Update on Share Repurchase Programme: Cumulative $5.4M
Gorilla successfully completed the repurchase of over $1.8 million worth of its own shares in April and May, capitalising on market dislocation and reinforcing its belief in the intrinsic value of the business. This strategic deployment of capital reflects the company's confidence in its growth trajectory, operational execution and long-term fundamentals.
This brings the company's cumulative share repurchases under the current buy-back programme to $5.4 million in the past twelve months, leaving $4.6 million remaining under the $10 million authorized by the Board. The company remains open to further opportunistic repurchases as cash buffers continue to strengthen.
Update on Insider Ownership: Approaches 20%
In a show of commitment and deep alignment with shareholder interests, the directors and officers of the company purchased additional shares in April and May during the permitted trading window. Collectively, Gorilla's management and Board of Directors now control nearly 20% of the Company, reinforcing insider confidence and vested interest.
Upcoming Earnings Release
Gorilla Technology will release its financial results for the first quarter of 2025 in the first half of June, which will be followed by an investor call. The company is poised to report continued progress across key markets including Southeast Asia, USA, Latin America and the UK, driven by its AI-powered smart infrastructure solutions. Call information will be circulated shortly.
About Gorilla Technology Group Inc.
Headquartered in London U.K., Gorilla is a global solution provider in Security Intelligence, Network Intelligence, Business Intelligence and IoT technology. We provide a wide range of solutions, including Smart City, Network, Video, Security Convergence and IoT, across select verticals of Government & Public Services, Manufacturing, Telecom, Retail, Transportation & Logistics, Healthcare and Education, by using AI and Deep Learning Technologies.
Our expertise lies in revolutionizing urban operations, bolstering security and enhancing resilience. We deliver pioneering products that harness the power of AI in intelligent video surveillance, facial recognition, license plate recognition, edge computing, post-event analytics and advanced cybersecurity technologies. By integrating these AI-driven technologies, we empower Smart Cities to enhance efficiency, safety and cybersecurity measures, ultimately improving the quality of life for residents.
For more information, please visit our website: Gorilla-Technology.com.
Forward-Looking Statements
This press release contains 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. Gorilla's actual results may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as 'expect,' 'estimate,' 'project,' 'budget,' 'forecast,' 'anticipate,' 'intend,' 'plan,' 'may,' 'will,' 'could,' 'should,' 'believes,' 'predicts,' 'potential,' 'might' and 'continues,' and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, statements regarding our beliefs about future revenues, our ability to attract the attention of customers and investors alike, Gorilla's ability to win additional projects and execute definitive contracts related thereto, along with those other risks described under the heading 'Risk Factors' in the Form 20-F Gorilla will file with the Securities and Exchange Commission (the 'SEC') on April 30, 2025 and those that are included in any of Gorilla's future filings with the SEC. These forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from expected results. Most of these factors are outside of the control of Gorilla and are difficult to predict. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Gorilla undertakes no obligation to update forward-looking statements to reflect events or circumstances after the date they were made except as required by law or applicable regulation.
Investor Relations Contact:
Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
[email protected]
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/253044
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Coherus BioSciences, Inc. (CHRS): A Bull Case Theory
We came across a bullish thesis on Coherus BioSciences, Inc. (CHRS) on Steve Wagner's Substack. In this article, we will summarize the bulls' thesis on CHRS. Coherus BioSciences, Inc. (CHRS)'s share was trading at $0.77 as of 30th May. CHRS's trailing P/E was 1.77 according to Yahoo Finance. Scientist in a lab working on a research project, focusing on biotechnology and healthcare advancements. Coherus BioSciences (CHRS), long overlooked by Wall Street, is taking a bold step into innovative oncology by partnering with UK-based STORM Therapeutics to test a novel cancer treatment strategy. The collaboration brings together Coherus's immunotherapy toripalimab (LOQTORZI) and STORM's first-in-class RNA-modifying enzyme inhibitor STC-15 in a Phase 1b/2 clinical trial. This unexpected pairing represents a fresh approach to immuno-oncology, targeting cancer through dual mechanisms that could produce synergistic effects. Toripalimab, already approved in the U.S. for nasopharyngeal carcinoma and under review for broader indications, offers proven checkpoint inhibition, while STC-15 introduces a cutting-edge method of disrupting RNA methylation processes linked to tumor growth and immune evasion. If this combo demonstrates efficacy, it could represent a completely new class of cancer therapy and place Coherus at the forefront of next-generation immuno-oncology innovation. Importantly, this partnership shows strategic vision from CHRS's management as they seek to differentiate the company beyond biosimilars and move deeper into proprietary immunotherapy. With the trial still in early stages and little market attention so far, the risk/reward profile for investors is potentially skewed to the upside. Should the data prove positive, the impact could be significant for both companies, especially for CHRS as it repositions itself as a serious player in oncology innovation. This under-the-radar development deserves close monitoring, as it could catalyze a major reevaluation of Coherus's valuation and growth trajectory. Previously, we have covered CHRS in March 2025 wherein we summarized a by the same author. Coherus BioSciences (CHRS) posted a strong turnaround in 2024 with $267M in revenue and $28.5M net income, driven by Loqtorzi's growth and the planned $250M Udenyca divestiture. The company pivoted fully to oncology, trimmed costs, and advanced its pipeline, yet management expressed frustration over the stock's undervaluation, hinting at potential M&A. Since our last coverage, the stock is down 38% as of 30th May. We don't trust CHRS' management as the stock lost more than 95% of its value in recent years and is still losing a ton of money. The market agrees with us and thinks this stock is going to go bankrupt. We believe CHRS should stop wasting shareholder's money, sell valuable assets, and liquidate the company. We don't think that's a likely outcome. Coherus BioSciences, Inc. (CHRS) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 10 hedge fund portfolios held CHRS at the end of the first quarter which was 10 in the previous quarter. While we acknowledge the potential of CHRS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Motor 1
an hour ago
- Motor 1
Bentley Has You Covered On Tariffs—For Now
If you're on the fence about which Bentley to park in your garage, it's time to jump: Bentley will honor pre-tariff pricing through the end of the month. Beyond that, what a new Bentley will cost you is anyone's guess. As the U.S. tariff situation changes with the wind, Bentley has said they'll reassess pricing in July. Bentley will continue to build and fulfill orders from US customers beyond the June window, but will halt dealer inventory moving into the country until July, keeping the vehicles in the U.K., until the situation becomes clearer. Get the best news, reviews, columns, and more delivered straight to your inbox, daily. back Sign up For more information, read our Privacy Policy and Terms of Use . For further clarification, Motor1 spoke with Bentley Chief Communications Officer Wayne Bruce during a first drive event for forthcoming models, which are under embargo. "Even now, at least until the end of June, you walk into a Bentley retailer, you order a Bentley, even if you configure a Bentley, it will be at the pre-tariff price," Bruce told Motor1. "Obviously, there are some [Bentley cars] on the ground [at pre-tariff prices] because [they were] imported before the tariffs. What we've also done currently though, is stop any retailer stock being shipped to the US until we get greater clarification on the new deal." 2026 Bentley Bentayga Speed Photo by: Bentley That means shoppers who want to walk into a Bentley showroom and drive out with a car will do so with strained inventory in the immediate future. The message from Bentley is clear: If you want a Bentley, this is the time to order, as the future's uncertain and further tariffs—or adjustments to current tariffs in place—could add costs for the customer. In response to the message, Bentley dealerships have received an influx of orders, Bruce said. "The dealers are very very happy right now." Beyond the end of June, however, we'll see if that holds. Contact the author: More Bentley News The New Bentley Bentayga Speed V-8 Outpunches the W-12 Bentley's New Bentayga Will Have 'More Power' Than the W-12 Bentley's New Hybrids Have Less Power—But Still a Lot of It Matt LeBlanc Drove This Bentley on Top Gear. You Can Buy It Bentley Made the Bentayga Even Fancier With the Atelier Edition Stellantis Wants To Take On Bentley Share this Story Facebook X LinkedIn Flipboard Reddit WhatsApp E-Mail Got a tip for us? Email: tips@ Join the conversation ( )
Yahoo
4 hours ago
- Yahoo
Britain to allocate $116 billion to R&D in spending plan
LONDON (Reuters) -British finance minister Rachel Reeves will allocate 86 billion pounds ($116 billion) in this week's spending review to fund research and development, the Department for Science, Innovation and Technology (DSIT) said on Sunday. It said the package, funding everything from new drug treatments and longer-lasting batteries to artificial intelligence breakthroughs, would be worth over 22.5 billion pounds a year by 2029/30, driving new jobs and economic growth. Reeves will divide more than 2 trillion pounds ($2.7 trillion) of public money between her ministerial colleagues on Wednesday, making choices that will define what the year-old Labour government can achieve in the next four years. The DSIT said the announcement on R&D follows Reeves' commitment last week to 15.6 billion pounds of government investment in local transport in city regions in the Northern England, Midlands and the South West. ($1 = 0.7398 pounds)
